Last checked at 
(Alliance News) - N4 Pharma PLC on Tuesday said it has signed a 14-month research collaboration with Nanomerics Ltd to produce and test two candidate formulations using its Nuvec delivery system.
The AIM stock was 9.2% higher in London in morning trade at 3.28 pence a share.
Nanomerics is focused on the development of pharmaceutical products with enhanced bioavailability.
The pharmaceutical company said the partnership will be split into two consecutive phases, each expected to last seven months.
Under the first phase, N4 Pharma said the companies will develop and test the 30-day stability of four different Nuvec formulations, using both a plasmid DNA and a small interfering RNA.
The second phase will involve testing the efficacy of the plasmid DNA in an in vivo antibody generation model, N4 Pharma said, and include the option to test the small interfering RNA antigen in a gene silencing tumour model.
"This is an exciting opportunity for the company to accelerate the development of its Nuvec delivery system," said Chief Executive Nigel Theobald.
"Demonstrating 30-day stability will be a major milestone in highlighting the potential for Nuvec to be used in a product and, by securing access to a novel small interfering RNA, the company will considerably broaden its data pack showing the versatility and utility of the Nuvec system," added Theobald.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
